Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.38 USD | -1.65% | -5.93% | +2.15% |
06-05 | VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201 | CI |
05-09 | Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.15% | 34.58M | |
+42.69% | 749B | |
+39.05% | 605B | |
-6.87% | 351B | |
+18.74% | 328B | |
+6.76% | 292B | |
+19.06% | 248B | |
-2.33% | 214B | |
+11.29% | 216B | |
+2.64% | 167B |
- Stock Market
- Equities
- VYNE Stock
- News VYNE Therapeutics Inc.
- Transcript : Foamix Pharmaceuticals Ltd., Q3 2019 Earnings Call, Nov 11, 2019